IIBR-100
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Other names | Brilife |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
IIBR-100 also known as Brilife is a COVID-19 vaccine candidate developed by The Israel Institute for Biological Research.[1][2]
References[edit]
- ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- ^ Jeffay N (29 December 2020). "As Israel goes vaccine-wild, will the homegrown version lose its shot?". The Times of Israel. Retrieved 1 January 2021.
External links[edit]
 |
Scholia has a profile for Brilife (Q100694835). |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |